Mozifor Injection contains Plerixafor, a selective CXCR4 chemokine receptor antagonist, available in a concentration of 24 mg/1.2 ml (20 mg/ml).
Mozifor is a specialised injectable medicine used mainly in stem cell mobilisation, helping collect more stem cells from the blood for transplantation. It is typically used in patients with certain cancers of the blood and bone marrow, such as multiple myeloma and non-Hodgkin’s lymphoma, who are scheduled to undergo an autologous stem cell transplant (ASCT).

Plerixafor works by a unique mechanism:

• It blocks the binding of stromal cell-derived factor-1α (SDF-1α) to the CXCR4 receptor on hematopoietic stem cells in the bone marrow.

• This disrupts the “anchoring” signals that normally keep stem cells within the marrow.

• As a result, more stem cells are released (mobilised) into the bloodstream, from where they can be collected by a process called apheresis for future transplantation.

This helps improve the chances of collecting an adequate number of stem cells, even in patients whose cells are harder to mobilise with growth factors alone.

Uses / Indications

Mozifor is indicated for:

• Mobilisation of hematopoietic stem cells into the peripheral blood for collection and subsequent autologous transplantation in patients with:

  • Multiple myeloma

  • Non-Hodgkin’s lymphoma

• It is used in combination with granulocyte-colony stimulating factor (G-CSF, e.g. filgrastim) to achieve optimal mobilisation.

This approach supports faster and more effective stem cell collection, improving transplant success rates.

Adverse Effects

While generally well-tolerated, Mozifor may cause side effects. Most are mild to moderate and temporary.
Common side effects include:

• Gastrointestinal disturbances: nausea, diarrhoea, bloating.

• Injection site reactions: redness, swelling, or discomfort.

• Dizziness, headache, or fatigue.

Less common but important to watch for:

• Transient increase in white blood cell (WBC) counts or spleen enlargement, which very rarely could lead to rupture (patients may be advised to report sudden abdominal pain).

• Allergic reactions (rash, itching, or breathing difficulty), though rare.

Because it mobilises many cells into the bloodstream, careful monitoring by the healthcare team is essential to manage counts and avoid complications.